Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

January 6, 2021January 6, 2021

Tiragolumab-Tecentriq Combo for NSCLC Earns Breakthrough Therapy Status

News

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to a combination of tiragolumab, a novel immunotherapy developed by Genentech, plus Tecentriq (atezolizumab) for the ... Read more

December 21, 2020December 21, 2020

Cancer Vaccines Get FDA Breakthrough Status in Advanced Melanoma Combo Therapy

News

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to a combination treatment of IO Biotech’s lead anti-cancer vaccine candidates IO102 and IO103, plus an ... Read more

December 9, 2020December 9, 2020

Tislelizumab Safely Prolongs Survival in Advanced Lung Cancer Patients, Interim Data Show

News

When given as a second- or third-line therapy, BeiGene’s tislelizumab is superior to docetaxel at prolonging the survival of people with locally advanced or metastatic non-small cell lung cancer (NSCLC), ... Read more

November 30, 2020November 30, 2020

Opdivo Approved in Europe as Second-line Therapy for Advanced Esophageal Cancer

News

The European Commission has approved Opdivo (nivolumab) as a second-line treatment for adults with advanced inoperable, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC), who previously were treated with fluoropyrimidine and ... Read more

November 25, 2020November 25, 2020

Merck Halts Phase 3 Trial on Yervoy-Keytruda Combo in Advanced Lung Cancer

News

Merck has decided to suspend its Phase 3 trial that was assessing a combination of Yervoy (ipilimumab) and Keytruda (pembrolizumab) as a first-line therapy for patients with advanced non-small cell lung ... Read more

November 13, 2020November 13, 2020

Keytruda-Chemo Combo Improves Survival Outcomes in Advanced Lung Cancer

News

First-line treatment with a combination of Keytruda (pembrolizumab) plus chemotherapy significantly prolongs survival, and extends life without disease progression, in people with advanced non-squamous non-small cell lung cancer (NSCLC), regardless ... Read more

November 6, 2020November 6, 2020

Tecentriq-Avastin Combo Approved in Europe for Advanced or Inoperable Liver Cancer

News

The European Commission has approved the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for adults with advanced or inoperable hepatocellular carcinoma (HCC), the most common form ... Read more

October 2, 2020October 2, 2020

Libtayo First-line Treatment Prolongs Survival in Advanced NSCLC, Early Trial Data Show

News

When given as a first-line therapy, Libtayo (cemiplimab) prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC), compared with platinum-based chemotherapy, according to early data from a ... Read more

September 30, 2020September 30, 2020

Keytruda Combo Shown to Extend Survival in Advanced Esophageal, GEJ Cancers

News

Adding Keytruda (pembrolizumab) to standard first-line chemotherapy significantly extends the survival of people with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) cancer, and also significantly lowers their risk ... Read more

September 21, 2020September 21, 2020

FDA Acts to Speed Toripalimab as Potential Nasopharyngeal Cancer Treatment

News

The U.S. Food and Drug Administration (FDA) has designated toripalimab (JS001) a breakthrough therapy as a potential treatment of nasopharyngeal carcinoma (NPC), one of the most common cancers in China and one lacking treatment ... Read more